Phase 2
Completed N=12
Cangrelor Ticagrelor Transition Study
Source: ClinicalTrials.gov NCT01766466 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
May 2014
Primary outcomePrimary: Extent of Preservation of Inhibitory Effect Compared With Effect Observed With Cangrelor Alone (at Timepoint 1, Either at 0.5 Hours or 1.25 Hours) or Ticagrelor Alone (Measured 5.25 Hours After Initiation of Cangrelor on Day 1) — 1.7; 1.3; 2; 2.2 percentage of platelet reactivity (PR)
Summary
To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Extent of Preservation of Inhibitory Effect Compared With Effect Observed With Cangrelor Alone (at Timepoint 1, Either at 0.5 Hours or 1.25 Hours) or Ticagrelor Alone (Measured 5.25 Hours After Initiation of Cangrelor on Day 1) |
1.7; 1.3; 2; 2.2; 2; 2.3 | — |
| PRIMARY Extent of Preservation of Inhibitory Effect Compared With Effect Observed During Cangrelor Treatment After Ticagrelor |
1.5; 1.5; 1.5; 1.3; 1.2; 1.5 | — |
| PRIMARY Extent of Aggregation Response During Ticagrelor Treatment |
4; 2.2; 5.8; 12; 11; 13 | — |
Eligibility Criteria
Inclusion Criteria
- greater than / equal to 18 and less than 75 years of age
- Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic q waves on at least 2 contiguous electrocardiogram (ECG) leads.
OR
- Previous revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery.
AND
- Treatment with aspirin (ASA) 81 mg daily.
Exclusion Criteria
Data sourced from ClinicalTrials.gov (NCT01766466). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.